Esperion announces new data from CLEAR outcomes on NEXLETOL

Esperion (ESPR) announced the presentation of two post hoc analyses from CLEAR Outcomes focused on: risk of major adverse cardiovascular event in ~8200 patients receiving no background lipid lowering therapies and risk of venous thromboembolism with bempedoic acid compared to placebo. These data were presented in oral and poster presentations, respectively, at the 2025 American Heart Association Scientific Sessions. Bempedoic acid monotherapy, LDL cholesterol and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial. Highlights: Over half of the 13,970 participants in CLEAR Outcomes were not receiving any background LLT during the study. Compared with placebo, bempedoic acid monotherapy lowered LDL-C by -20.6% at 6 months and reduced MACE-4 by 14%. Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial. Highlights: Treatment with bempedoic acid in patients with statin intolerance and at high risk for, or with established cardiovascular disease, was associated with a reduction in venous thromboembolic events. In total, 106 VTE events occurred over 40.6 months of follow up. Compared with placebo, bempedoic acid reduced the risk of any VTE by 42%